In these studies, the role of T helper and T cytotoxic cells in generating intestinal graft-vs.-host disease (GVHD) was examined. Treatment of C57BL/6J (B6) splenocytes with L-leucyl-L-leucine methyl ester (Leu-Leu-OMe) selectively removes natural killer cells, cytotoxic T lymphocyte (CIL) precursors, and the capacity to cause lethal GVHD in irradiated B6xDBA/2 Fl (B6D2Fl) mice while preserving T helper cell function. Neither control nor Leu-Leu-OMe-treated DBA/2 donor spleen and bone marrow cells were found to induce lethal GVHD in B6D2F1 recipients. However, extensive colonic GVHD developed in B6D2F1 recipients of DBA/2 bone marrow and spleen cells. Enteropathic GVHD in DBA/2 -* B6D2F1 mice was reduced in severity after anti-L3T4 + C treatment of donor cells, and was eliminated by anti-Thyl.2 + C or the combination of anti-L3T4 and anti-Lyt2 + C treatment of the donor cell inoculum. However, neither antiLyt2 + C, Leu-Leu-OMe, nor anti-Lyt2 + C and Leu-LeuOMe treatment of donor cells significantly decreased severity of gut GVHD. Leu-Leu-OMe treatment of DBA/2 or B6 SpC was comparably effective in preventing in vitro or in vivo generation of B6D2Fl-specific CiL. These findings, therefore, demonstrate that histologically severe enteropathic GVHD does not require participation of CIL and is not always associated with high mortality rates.
Introduction
Transfer of T cells to allogeneic, immunocompromised hosts causes graft-vs.-host disease (GVHD) (1) (2) (3) (4) (5) . 1 This syndrome is associated with lesions of the skin, liver, intestinal tract, and lymphoid organs and is a major cause of morbidity and mortality following bone marrow transplantation (6, 7) . The specific T cell functions that are required to initiate or propagate various aspects of this syndrome have not been clearly defined (8) . The clinical manifestations of GVHD induced by transfer of T cells that recognize only class I major histocompatibility complex (MHC) antigens, class II MHC antigen alone, or non-MHC antigen disparities have been noted to differ (8-1 1) . Moreover, the spectrum of lesions induced by CD4(+) and CD8(+) T cell subsets has also been noted to differ. Despite the differences, however, considerable overlap in the features of GVHD induced in these various situations is also apparent (8) .
The fact that both CD4(+) and CD8(+) T cell subsets can give rise to cytotoxic T lymphocytes (CTL) and produce lymphokines when stimulated with appropriate class II or class I MHC antigens (12-16) may explain the many common features of GVHD induced by specific histocompatibility antigen disparities or from phenotypically distinct T cell subsets.
Previous studies in our laboratory have noted that lethal GVHD induced in irradiated B6D2F1 (H-2bd) mice by transfer of B6 (H-2b) parental bone marrow cells (BMC) and spleen cells (SpC) is prevented by a brief preincubation of donor cells with L-leucyl-L-leucine methyl ester (Leu-LeuOMe) (17, 18) . Exposure of human or murine lymphocytes to Leu-Leu-OMe results in depletion of all natural killer (NK) cells and a fraction of T cells ( 18, 19) . After exposure to this agent, B cells and T helper cells are largely preserved, whereas the capacity to generate CTL from both CD4(+) or CD8(+) subsets is ablated (18, 19) . Thus, the salutary effect of LeuLeu-OMe treatment of donor cells on the course of GVHD in B6 -> B6D2Fl mice suggests that cytotoxic lymphocytes play an essential role in the evolution of GVHD in this class I + II MHC antigen and multiple non-MHC antigen disparate strain combination. Furthermore, inasmuch as depletion of CD4(+) T cells, CD8(+) T cells, or NK cells alone does not prevent lethal GVHD in this strain combination (17, 18) , these findings demonstrated that Leu-Leu-OMe treatment ofdonor cells offers a unique approach to prevention of this complication of bone marrow transplantation.
A number of investigators have noted that transfer of DBA/2 as opposed to B6 parental spleen cells into unirradiated B6D2Fl mice results in distinctively different patterns of GVHD (20) (21) (22) (23) . DBA/2 -o B6D2F1 mice develop an alloproliferative syndrome which has been attributed to the helper effects of alloreactive DBA/2 CD4(+) donor cells (20) (21) (22) (23) . The effects of transferring DBA/2 SpC into irradiated B6D2F1 have not been studied as extensively, nor has the nature of the effector cells inducing GVHD.
The current studies were, therefore, undertaken to examine the clinical manifestations of GVHD in this strain combination and the role of CTL in the induction of this syndrome. It was found that transfer of DBA/2 BMC and SpC to irradiated B6D2F1 mice rarely led to lethal GVHD. However, intestinal GVHD was readily apparent in B6D2F1 recipients of DBA/2 BMC and SpC. Treatment of the donor inoculum with Leu-Leu-OMe had no effect on the evolution of intestinal GVHD in this strain combination. These findings demonstrate that histologically severe enteropathic GVHD does not require the participation of CTL and is not always associated with high rates of mortality.
Methods
Mice. C57BL/6J (B6), (C57BL/6JxDBA/2J)F1(B6D2F1), and DBA/2J (DBA/2) female mice were purchased from the Jackson Laboratory, Bar Harbor, ME.
Medium. RPMI 1640 (Hazleton Research Products, Denver, PA), supplemented with 5 mM Hepes, 1 mM sodium pyruvate, 5 X 10-5 M 2-mercaptoethanol, penicillin G (200 U/ml), gentamicin (10 Ag/ml), and L-glutamine (0.3 mg/ml), was used for cell cultures. When used in cytotoxicity assays, medium was supplemented with 10% fetal bovine serum (FBS, Hazleton Research Products), whereas medium was supplemented with 2% human serum for use in mixed lymphocyte cultures.
Antibodies. Anti-Thyl.2 (HO-13-4), anti-L3T4 (GKl.5), antiLyt-2 (3.155), anti-Lyt2.2 (HO2.2), and anti-Lyt 2.1 (116-13.1) were culture supernatants or ascitic fluid produced from hybridoma cells obtained from the American Type Culture Collection, Rockville, MD (24) (25) (26) (27) (28) .
Rat concanavalin A (Con A) supernatant. Rat (Sprague-Dawley, Sasco Inc., Omaha, NE) spleen cells (107/ml) were suspended in medium supplemented with 10% FBS, 20 ,g/ml of Con A, and 10-' g/ml 4,B-phorbol 12-myristate-13-acetate (Sigma Chemical Co., St. Louis, MO) for 4 h at 37°C in 95% air, 5% CO2 atmosphere. Rat spleen cells were then washed twice with Hanks' balanced salt solution (HBSS) supplemented with 0.1 M methyl a-D-mannopyranoside (Sigma Chemical Co.) and then twice more with HBSS. Spleen cells were then resuspended (107/ml) in medium supplemented with 10% FBS and cultured for 24 h before collection of cell-free culture supernatant.
EL4 supernatant. Cells from the EL4.IL2 subline of the murine EL4 lymphoma line ( 107/ml, American Type Culture Collection) were cultured with 20 ng/ml phorbol dibutyrate in medium supplemented with 10% FBS for 24 h. Cell-free culture supernatant was then harvested and extensively dialyzed (10,000-mol wt exclusion membranes) to remove excess phorbol dibutyrate before use in cell cultures.
Cell preparation. Femurs and tibias were dissected free of muscle and connective tissue, crushed with a sterile porcelain mortar and pestle, and then filtered through sterile nylon mesh. BMC were then washed with HBSS. Spleens were minced and filtered through sterile nylon mesh and the SpC were then washed with HBSS. For depletion ofThy Incubation with Leu-Leu-OMe. Leu-Leu-OMe was synthesized from leucyl-leucine (Sigma Chemical Co.) as described (29) . Cells were washed and were suspended (2.5-10 X 106/ml) in PBS and were incubated for 15 Cell-mediated cytotoxicity assays. Splenic blast cells were induced by a 2-d incubation with lipopolysaccharide (LPS, 50 ug/ml; Escherichia coli 027:B8, Difco Laboratories, Inc., Detroit, MI) and dextran sulfate (20 ug/ml, mean mol wt 500,000, Sigma Chemical Co.) in culture medium supplemented with 10% FBS. Alloantigen-specific killing against stimulator lymphoblasts was assessed in 4-h 5"Crrelease assays, and the percentage of specific lysis was calculated as described (30) .
Transplantation. Recipients were maintained on acidified (pH 2), antibiotic (neomycin, 100 mg/liter, and polymyxin B, 10 mg/liter) H20 for 2-3 d before and 7 d after transplantation. On the day of transplantation, recipients were irradiated (900 cGy) and 2-6 h later were injected via the lateral tail vein with donor cells in 0.5 ml of HBSS. Histologic evaluation ofgastrointestinal GVHD. Mice were killed and the viscera were removed intact and fixed in 10% Carson's formalin. From each mouse, six sections ofcolon (two from cecum, two from transverse colon, and two from descending colon) were paraffin embedded and 4-5-Aim sections were stained with hematoxylin and eosin for examination by light microscopy. Because of loss in processing, only four or five colon sections were available in four of the 36 mice examined. Microscopic sections were examined in a blinded fashion by the same observer (Dr. M. Eigenbrodt) and severity of seven distinct histologic features was graded. These seven features ofGVHD were (a) mononuclear leukocyte infiltration of the mucosa and submucosa, (b) polymorphonuclear leukocyte infiltration of the mucosa and submucosa, (c) mononuclear leukocyte infiltration of the mesenteric fat and blood vessels, (d) polymorphonuclear leukocyte infiltration of the mesenteric fat and blood vessels, (e) increased epithelial cell proliferation in the crypts ofLieberkuhn, (f) increased mucosal surface epithelial proliferation, and (g) loss of goblet cells.
Mononuclear cell and granulocytic inflammatory infiltrates were graded on a scale from 0 (no increased inflammatory cells) to 3+ (marked infiltration with inflammatory cells). Nuclear crowding in intestinal crypt and surface epithelium and surface proliferative changes were separately evaluated as markers of the increased rate of intestinal epithelial cell proliferation which is induced by GVHD. Nuclear crowding varied from normal epithelium (0+) to 3+ changes in which epithelial cells in the outer one-third of the crypts contained large hyperchromatic nuclei with pseudostratification which imparted an adenomatous appearance. Surface proliferations varied from normal surface architecture (0+) to changes associated with extensive piling up of cells to form papillary structures (3+). Loss of goblet cells was evaluated with abnormalities varying from no loss of goblet cells (0+) to total absence of goblet cells (3+).
Other features that were sometimes observed included increased gut wall thickness and edema, crypt abscesses, lymphatic dilatation, lymphatic cellular collections or thrombi, and blebs formed by separation of the surface epithelium from the underlying lamina propria. These features were frequently focal and were not scored or grouped with the various diffuse histologic abnormalities in calculation of an overall severity score. When severity scores of the cecum, the transverse colon and the descending colon were compared, no statistically significant differences (Newman-Keuls multiple comparison procedure) in severity ofany category of histologic lesion were noted. Therefore, the severity ofeach histologic lesion in individual mice is reported as the means ofthe scores recorded for the sections obtained from these three areas of the colon.
In vivo CTL generation. To Fig. 2 , A-C, irradiated B6D2F1 recipients of control ( Fig. 2 A) or Leu-Leu-OMe-treated ( Fig. 2 B) DBA/2 BMC and SpC were found to have extensive colonic inflammatory lesions. Histologic abnormalities in the colons of these mice were characterized by lymphocytic infiltration of the lamina propria, submucosa and mesenteric fat with dilatation of vessels in the submucosa and muscularis propria, thinning of the muscularis propria, and loss of mucosal goblet cells. Areas of -.
0. In additional studies, the effects of Leu-Leu-OMe treatment on allocytotoxic responses of DBA/2 and B6 SpC were examined (Table II) . As demonstrated by the results of experiments 1 and 2, Leu-Leu-OMe treatment of B6 or DBA/2 SpC abolished the capacity to generate B6D2F1-specific CTL in mixed lymphocyte cultures. Experiments 3 and 4 in Table II were designed to examine the effects of Leu-Leu-OMe treatment on generation of CTL from L3T4(+) T cells. Because L3T4(+) CTL generation is best demonstrated after culture of Lyt2(-) responder cells in mixed lymphocyte cultures supplemented with T cell lymphokines (32), Con A-stimulated rat SpC supernatants (10%, vol/vol) were added to these cultures. As can be seen in experiments 3 and 4 in Table II , CTL could be generated from both unseparated SpC and Lyt2 depleted SpC. Generation of CTL from each population was prevented by treatment with Leu-Leu-OMe. The CTL generated from Lyt2 depleted SpC were resistant to anti-Lyt2 + C treatment (Table II) vivo evolution of anti-B6D2Fl specific responses generated from each parental strain might be different. The experiments detailed in Table III were, therefore, designed to assess in vivo CTL generation after transfer of control or Leu-Leu-OMetreated donor SpC to irradiated B6D2Fl mice. To accomplish this, B6 or DBA/2 donor spleen cells were infused into irradiated B6D2Fl mice and recipient spleen cells were harvested at varying time intervals after transplantation. Cells capable of lysing H-2bd-bearing B6D2Fl target cells could be detected in SpC obtained from irradiated B6D2Fl recipients ofcontrol B6 or DBA/2 spleen cells. However, as previously reported (33) , the ability to detect in vivo CTL generation was greatly enhanced without loss of specificity when SpC were cultured overnight in medium supplemented with T cell lymphokines before cytotoxicity assays. As demonstrated in Table III , antiB6D2Fl-specific CTL were detected in SpC populations obtained from irradiated B6D2Fl recipients of control B6 or DBA/2 donor cells. However, SpC obtained from B6D2Fl recipients of Leu-Leu-OMe-treated B6 or DBA/2 SpC manifested no anti-B6D2Fl cytotoxicity, regardless of when the mice were sacrificed after transplantation.
Colonic GVHD in DBA/2 --B6D2FJ mice can be generated by transfer ofLeu-Leu-OMe-resistant L3T4(+) T helper cells alone. As anti-B6D2F 1-specific CTL could not be generated from Leu-Leu-OMe-treated DBA/2 SpC, the gastrointestinal GVHD developing in irradiated B6D2Fl recipients of Leu-Leu-OMe-treated DBA/2 spleen cells was likely to be generated by effector mechanisms distinct from classic T cell cytotoxicity. The studies detailed in Fig. 3 Fig. 3 ). In contrast, recipients of control DBA/2 bone marrow and SpC developed statistically significant degrees of abnormalities in each of the seven histologic categories (group A, Fig. 3 ). LeuLeu-OMe treatment of donor SpC before transfer to B6D2Fl recipient mice had no statistically significant effect on the severity of gastrointestinal GVHD lesions as determined either by assessment of individual pathologic parameters or by the total enteropathy score (group B, Fig. 3 ). When the capacity of T cell subsets to initiate GVHD was examined, it was noted that the overall severity of gastrointestinal GVHD generated by L3T4(+) donor T cells (group C) was significantly greater than that generated by Lyt2(+) donor T cells (group E), although each T cell subset induced more severe pathologic Fig. 3 ). Although the mean severity of colonic GVHD induced by L3T4(+) donor T cells (group C) was greater than that induced by Lyt2(+) T cells (group E) in each of the histologic categories assessed, these differences achieved statistical significance only in assessment of the two aspects of mesenteric inflammation and in the total enteropathy scores. The lack of requirement for CTL responses in the development of gastrointestinal GVHD was confirmed by the observation that anti-Lyt2 + C and Leu-Leu-OMe-treated DBA/2 donor SpC also caused colonic GVHD lesions in B6D2Fl recipients (groups C and D, respectively) that were not discernibly different from those seen in recipients of control DBA/2 SpC (group A). Of note, however, Leu-Leu-OMe treatment of L3T4(+) cells did result in a statistically significant decrease in the severity of mesenteric inflammation but not in other individual measures of severity or in the overall enteropathy score (group D vs. group C, Fig. 3 ). The studies detailed in Fig. 3 suggested that either L3T4(+) or Lyt2(+) DBA/2 splenic T cells could induce intestinal GVHD in irradiated B6D2Fl recipients. However, inasmuch as these donor T cell subsets were isolated by MAb + C-mediated depletion of the reciprocal T cell subset, it remained possible that Thy 1.2(+), L3T4(-), Lyt2(-) DBA/2 T cells were the critical donor T cell population responsible for generating this enteropathic syndrome. The experiment detailed in Table IV was therefore performed. Again, transfer ofcontrol DBA/2 bone marrow and spleen cells to irradiated B6D2F1 recipients was associated with development ofsevere intestinal GVHD. However, either anti-Thy 1 .2 + C or combined anti-L3T4 and anti-Lyt2 + C treatment of DBA/2 donor SpC was found to ablate the capacity to generate significant intestinal GVHD in B6D2FI recipients. GVHD in this model cannot be accounted for by the activity ofan L3T4(-), Lyt2(-) T cell but rather is caused by either L3T4(+) or Lyt2(+) effector T cells.
Discussion
Gastrointestinal involvement is a major cause of morbidity from human GVHD. In both human and murine models of GVHD, high mortality rates are frequently seen in association 1 and 2) for the capacity to lyse B6D2FI lymphoblasts or were treated with complement alone or with anti-Lyt2, anti-Lyt2.2 and C (experiment 3) or anti-Lyt2, anti-Lyt2. 1 and C (experiment 4) before assay of allospecific cytotoxicity. with more severe forms ofgut GVHD. A striking feature ofthe current studies, however, is the disparity between mortality and severe gastrointestinal involvement as well as the manner in which these two manifestations ofGVHD are modulated by Leu-Leu-OMe treatment ofdonor cells. Thus, DBA/2 donor T cells generate severe colonic GVHD in irradiated B6D2Fl recipients, but lethal disease did not develop in this strain combination. Furthermore, Leu-Leu-OMe treatment of donor cells had no significant effect on the severity of the tissue damage generated in the colons of B6D2Fl recipients of DBA/2 donor T cells. In contrast, similar treatment of B6 donor T cells consistently prevented the development of lethal GVHD (18) .
Because Leu-Leu-OMe treatment of DBA/2 or B6 SpC was similarly effective in preventing in vitro or in vivo generation of B6D2Fl-specific CTL, these findings indicate that T cellmediated cytotoxicity does not play an essential role in the cascade of donor anti-host immune responses that generate gastrointestinal GVHD. In contrast to the B6 -* B6D2FI and many other parent F1 strain combinations, transfer of control DBA/2 donor SpC and bone marrow to lethally irradiated B6D2F1 recipients does not generate lethal GVHD despite the presence of class I and II MHC and multiple non-MUC encoded histocompatibility antigen differences. Rolink and Gleichmann as well as other groups of investigators have noted the dichotomy between the acutely lethal "allosuppressive" GVHD induced by B10 or B6 donor cells, and the relatively less lethal "lymphoproliferative" GVHD induced by DBA/2 donor cells in nonirradiated Fl recipients (20, 22, 23 B6xCBAFl . In these latter strains, mortality was commonly observed when the recipients received control and not Leu-Leu-OMe-treated donor cells, whereas diarrhea was observed when animals received Leu-Leu-OMe-treated cells (data not shown). The fact that long-term survival was uniformly observed in these mice despite development of severe transmural intestinal GVHD suggests that other aspects ofGVHD such as the profound immunosuppression reported to be present in B6 -* B6D2F1 GVHD mice but not in DBA/2 --B6D2Fl mice (20-22) or B6D2Fl recipients of Leu-Leu-OMe treated B6 donor cells (31) might be a far more important determinant of overall mortality rates. Indeed, even in the B6 --B6D2Fl strain combination in which recipients of Leu-Leu-OMe-treated donor cells consistently fail to exhibit clinically apparent wasting or diarrhea (17, 18, 31) , histologic evaluation 4 wk after transplantation has also demonstrated extensive colonic inflammatory changes (data not shown). Since the early mortality observed in many strain combinations prevents detailed chronologic evaluation of enteropathic GVHD, the uniformly prolonged survival of B6D2Fl recipients of DBA/2 donor T cells afforded an opportunity to examine in detail the features of intestinal GVHD generated by various donor T cell populations.
It has been clearly demonstrated that introduction of mature T cells into an allogeneic host is essential for the generation of the mortality and organ-specific tissue injury associated with the syndrome of acute GVHD. However, the individual role of various T cell subsets and their functional activities has been more difficult to delineate. The nature of intestinal GVHD generated in strain combinations with isolated class I MHC or class II MHC or in class I +11 MHC disparate recipients of L3T4(+) and Lyt2(+) donor T cells has led other investigators to suggest that L3T4(+) donor T cells responding to host class II MHC encoded histocompatibility antigen play a major role in generating such lesions (10, 34, 35) . The recent demonstration that treatment of GVHD mice with antibody to tumor necrosis factor greatly reduced both mortality and the severity of intestinal GVHD (36) has suggested that the role of donor T cells in generating the gut lesions of GVHD may be mediated largely through alloantigen-stimulated induction of cytokine release. As T cells removed from the spleens or intestines of mice undergoing GVHD induced by isolated class II MHC disparities or by Lyt2(-) donor T cells have been found to contain little or no anti-host CTL activity when assessed immediately after isolation (10, 34) , it has been suggested that CTL may play little or no role in the GVHD lesions generated by L3T4(+) donor T cells responding to host (10, 33) . Thus, a role for donor anti-host CTL in the development of various aspects of enteropathic GVHD cannot be excluded by studies relying solely on use of It is not surprising that the submucosal edema and inflammatory infiltrates seen in intestinal GVHD are solely dependent on donor anti-host helper T cell responses. However, in the DBA/2 -) B6D2F1 model of intestinal GVHD, a variety of destructive lesions are also generated as evidenced by the presence of crypt abscesses, goblet cell loss, and increased epithelial cell turnover. The fact that each of these lesions was readily apparent in B6D2Fl recipients of CTL depleted DBA/2 donor cells indicates that such lesions can also be initiated by donor helper T cells. Presumably, these manifestations ofgut GVHD are initiated by the lymphokine response ofsuch alloreactive donor T cells. Whether such intestinal epithelial cell damage is mediated by the direct effect of T cell products such as tumor necrosis factor (35) , or indirectly through the activation of NK, macrophages, or PMN, remains to be delineated.
In summary, our studies have used the DBA/2 -* B6D2Fl murine model of bone marrow transplantation and GVHD to examine the nature ofdonor T functions which are required to generate GVHD enteropathy. The results indicate that a broad spectrum of intestinal histologic abnormalities are generated by donor anti-host T cell responses distinct from cell-mediated cytotoxicity. Furthermore, the dichotomy between the prolonged long-term survival of DBA/2 -> B6D2F1 mice and the severity of colonic GVHD lesions generated in these animals suggests that other aspects of GVHD may be more important in determining mortality.
